Measurement and predictors of adherence in a trial of HSV suppressive therapy in Tanzania

Contemporary Clinical Trials

Volumn 30, Issue 6, 2009, Pages 504-512

  Watson Jones, Deborah ^a,b   Baisley, Kathy ^a,c   Rusizoka, Mary ^b   Tanton, Clare ^a,c   Mugeye, Kokugonza ^b   Weiss, Helen A ^a   Changalucha, John ^c   Clayton, Tim ^a   Hambleton, Ian ^a,c   Ross, David A ^a   Hayes, Richard J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b African Medical and Research Foundation Mwanza   (Tanzania)

^c NATIONAL INSTITUTE OF MEDICAL RESEARCH   (Tanzania)

Author keywords

Acyclovir; Clinical trial; HSV 2; Patient compliance; Tanzania

Indexed keywords

ACICLOVIR; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALARIA; MEASUREMENT; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PREGNANCY TEST; RANDOMIZED CONTROLLED TRIAL; SCREENING; TABLET; TANZANIA; TREATMENT DURATION; URINALYSIS;

ACYCLOVIR; ADOLESCENT; ADULT; AGE FACTORS; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESIDENCE CHARACTERISTICS; SOCIOECONOMIC FACTORS; TANZANIA; YOUNG ADULT;

EID: 70350754340     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2009.07.002     Document Type: Article

References (35)

1. Freeman E.E., Weiss H.A., Glynn J.R., et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20 (2006) 73-83
2. Wald A., and Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185 (2002) 45-52
3. Sobngwi-Tambekou J., Taljaard D., Lissouba P., et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 199 (2009) 958-964
4. Schacker T., Ryncarz A.J., Goddard J., Diem K., Shaughnessy M., and Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280 (1998) 61-66
5. McClelland R.S., Wang C.C., Overbaugh J., et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 16 (2002) 2425-2430
6. Baeten J.M., McClelland R.S., Corey L., et al. Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. J Infect Dis 189 (2004) 1466-1471
7. Nagot N., Ouedraogo A., Foulongne V., et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 356 (2007) 790-799
8. Delany S., Mlaba N., Clayton T., et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 23 (2009) 461-469
9. Zuckerman R.A., Lucchetti A., Whittington W.L., et al. Herpes simplex virus (HSV) suppression with valaciclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 196 (2007) 1500-1508
10. Cowan F.F., Pascoe S.J., Barlow K.L., et al. Association of genital shedding of herpes simplex virus type 2 and HIV-1 among sex workers in rural Zimbabwe. AIDS 20 (2006) 261-267
11. Baeten J.M., Strick L.B., Lucchetti A., et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 198 (2008) 1804-1808
12. Dunne E.F., Whitehead S., Sternberg M., et al. Suppressive aciclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 49 (2008) 77-83
13. Watson-Jones D., Weiss H.A., Rusizoka M., et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 358 (2008) 1560-1571
14. Tanton C., Watson-Jones D., Rusizoka M., et al. A randomized controlled trial in Tanzania to assess the impact of HSV-2 suppressive therapy on genital HIV viral load among HSV-2 and HIV-1 seropositive women. 4th International AIDS Society Conference on HIV Pathogenesis. Treatment & Prevention (2007) July 22-25, 2007. Abstract No. TUPEC011.; Sydney. 2007
15. Watson-Jones D., Weiss H.A., Rusizoka M., et al. Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial. J Acquir Immune Defic Syndr 46 (2007) 631-642
16. Loregian A., Gatti R., Palu G., and De Palo E.F. Separation methods for aciclovir and related antiviral compounds. J Chromatogr B Biomed Sci Appl 764 (2001) 289-311
17. Peterson L., Taylor D., Roddy R., et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2 (2007) e27
18. Padian N.S., van der Straten A., Ramjee G., et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 370 (2007) 251-261
19. Weiss H.A., Wasserheit J.N., Barnabas R.V., Hayes R.J., and Abu-Raddad L.J. Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol 5 (2008) 8
20. Celum C., Wald A., Hughes J., et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008) 2109-2119
21. Straka R.J., Fish J.T., Benson S.R., and Suh J.T. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 17 (1997) 126-132
22. Arnsten J.H., Demas P.A., Farzadegan H., et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 33 (2001) 1417-1423
23. Rudd P., Byyny R.L., Zachary V., et al. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 46 (1989) 169-176
24. Bova C.A., Fennie K.P., Knafl G.J., Dieckhaus K.D., Watrous E., and Williams A.B. Use of electronic monitoring devices to measure antiretroviral adherence: practical considerations. AIDS Behav 9 (2005) 103-110
25. Muyingo S.K., Walker A.S., Reid A., et al. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr 48 (2008) 468-475
26. Bii S.C., Otieno-Nyunya B., Siika A., and Rotich J.K. Self-reported adherence to single dose nevirapine in the prevention of mother to child transmission of HIV at Kitale District Hospital. East Afr Med J 84 (2007) 571-576
27. Berg K.M., Demas P.A., Howard A.A., Schoenbaum E.E., Gourevitch M.N., and Arnsten J.H. Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med 19 (2004) 1111-1117
28. Bangsberg D.R., Hecht F.M., Charlebois E.D., Chesney M., and Moss A. Comparing objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unaccounced pill counts. AIDS Behav 5 (2001) 275-281
29. Bangsberg D.R., Hecht F.M., Charlebois E.D., et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14 (2000) 357-366
30. Jefford M., and Moore R. Improvement of informed consent and the quality of consent documents. Lancet Oncol 9 (2008) 485-493
31. Demas P.A., Thea D.M., Weedon J., et al. Adherence to zidovudine for the prevention of perinatal transmission in HIV-infected pregnant women: the impact of social network factors, side effects, and perceived treatment efficacy. Women Health 42 (2005) 99-115
32. Miller L.G., and Hays R.D. Measuring adherence to antiretroviral medications in clinical trials. HIV Clin Trials 1 (2000) 36-46
33. Reitano M., Tyring S., Lang W., et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis 178 (1998) 603-610
34. Conant M.A., Schacker T.W., Murphy R.L., et al. Valaciclovir versus aciclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS 13 (2002) 12-21
35. Gupta R., Wald A., Krantz E., et al. Valaciclovir and aciclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis 190 (2004) 1374-1381